Emergent BioSolutions to buy Adapt Pharma in $735m deal
Adapt Pharma is a privately-held company committed to expanding affordable access to Narcan (naloxone HCI) nasal spray and to progressing treatment options in the field of addiction. The
MinervaX, a Danish biotechnology company, has joined forces with contract development and manufacturing organisation (CDMO) Wacker Biotech for the manufacturing of MinervaX’s active protein ingredients for its Group B Streptococcus (GBS) vaccine.
Onvansertib is a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. Trovagene executive chairman Dr Thomas Adams said: “The European Commission’s decision to grant orphan